Antibody therapeutic prediction and design : immunogenicity and stability

One third of all drugs currently in development are monoclonal antibody therapeutics. Key to the efficacy and safety of therapeutic antibodies is the avoidance of immunogenic reaction upon administration. Immunogenicity describes a patient’s immune response to an antibody therapeutic that leads to p...

Full description

Bibliographic Details
Main Author: Northey, T. C.
Other Authors: Martin, A. C. R. ; Shepherd, A.
Published: University College London (University of London) 2017
Subjects:
570
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.746395
id ndltd-bl.uk-oai-ethos.bl.uk-746395
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7463952019-03-05T15:54:00ZAntibody therapeutic prediction and design : immunogenicity and stabilityNorthey, T. C.Martin, A. C. R. ; Shepherd, A.2017One third of all drugs currently in development are monoclonal antibody therapeutics. Key to the efficacy and safety of therapeutic antibodies is the avoidance of immunogenic reaction upon administration. Immunogenicity describes a patient’s immune response to an antibody therapeutic that leads to poor drug efficacy and allergic reaction that can vary in severity. Immunogenicity is influenced both by the presence of T and B cell epitopes and by antibody stability. The aim this thesis was to develop in silico methods to aid the selection and design of antibody therapeutics by focusing on the prediction B-cell epitopes and biophysical stability. IntPred, an in-house high-performance general protein-protein interface predictor, was applied to the problem of B cell epitope prediction. Tested on set of antigen structures, IntPred was shown be unable to predict B cell epitopes. Thus, IntPred was retrained and amended to create the IntPred:Epi method. IntPred:Epi was able to outperform all methods tested, except SEPPA 2.0. However, further testing on larger test set shows that IntPred:Epi outperforms SEPPA 2.0. Next, the influence of ‘tolerated surfaces’ on the selection of epitopes was considered. Specifically, libraries of surfaces were created through analysis and generalization of human and mouse PDB structures. From these, descriptors were generated to describe the tolerance state of an antigen surface. These were then applied as a novel label in the B cell epitope prediction problem. Using tolerance labels as a simple filter on IntPred:Epi predictions, performance was improved on a test set of human antibody-bound antigens. The efficacy and immunogenicity of a therapeutic antibody is also affected by its stability. Natural VH-VL pair human Fabs were expressed and sequenced, and hydrophobicity and thermal stability data were generated. These data were then used to investigate the sequence determinants of the biophysical properties of antibodies. An exploratory analysis revealed promising correlations between certain sequence features and biophysical properties that can be applied in the future for the prediction of biophysical stability.570University College London (University of London)https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.746395http://discovery.ucl.ac.uk/1536344/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 570
spellingShingle 570
Northey, T. C.
Antibody therapeutic prediction and design : immunogenicity and stability
description One third of all drugs currently in development are monoclonal antibody therapeutics. Key to the efficacy and safety of therapeutic antibodies is the avoidance of immunogenic reaction upon administration. Immunogenicity describes a patient’s immune response to an antibody therapeutic that leads to poor drug efficacy and allergic reaction that can vary in severity. Immunogenicity is influenced both by the presence of T and B cell epitopes and by antibody stability. The aim this thesis was to develop in silico methods to aid the selection and design of antibody therapeutics by focusing on the prediction B-cell epitopes and biophysical stability. IntPred, an in-house high-performance general protein-protein interface predictor, was applied to the problem of B cell epitope prediction. Tested on set of antigen structures, IntPred was shown be unable to predict B cell epitopes. Thus, IntPred was retrained and amended to create the IntPred:Epi method. IntPred:Epi was able to outperform all methods tested, except SEPPA 2.0. However, further testing on larger test set shows that IntPred:Epi outperforms SEPPA 2.0. Next, the influence of ‘tolerated surfaces’ on the selection of epitopes was considered. Specifically, libraries of surfaces were created through analysis and generalization of human and mouse PDB structures. From these, descriptors were generated to describe the tolerance state of an antigen surface. These were then applied as a novel label in the B cell epitope prediction problem. Using tolerance labels as a simple filter on IntPred:Epi predictions, performance was improved on a test set of human antibody-bound antigens. The efficacy and immunogenicity of a therapeutic antibody is also affected by its stability. Natural VH-VL pair human Fabs were expressed and sequenced, and hydrophobicity and thermal stability data were generated. These data were then used to investigate the sequence determinants of the biophysical properties of antibodies. An exploratory analysis revealed promising correlations between certain sequence features and biophysical properties that can be applied in the future for the prediction of biophysical stability.
author2 Martin, A. C. R. ; Shepherd, A.
author_facet Martin, A. C. R. ; Shepherd, A.
Northey, T. C.
author Northey, T. C.
author_sort Northey, T. C.
title Antibody therapeutic prediction and design : immunogenicity and stability
title_short Antibody therapeutic prediction and design : immunogenicity and stability
title_full Antibody therapeutic prediction and design : immunogenicity and stability
title_fullStr Antibody therapeutic prediction and design : immunogenicity and stability
title_full_unstemmed Antibody therapeutic prediction and design : immunogenicity and stability
title_sort antibody therapeutic prediction and design : immunogenicity and stability
publisher University College London (University of London)
publishDate 2017
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.746395
work_keys_str_mv AT northeytc antibodytherapeuticpredictionanddesignimmunogenicityandstability
_version_ 1718998072544985088